FDA Inspection 1149183 — Lianyungang Kangle Pharmaceutical Co., Ltd.
The FDA completed an inspection of Lianyungang Kangle Pharmaceutical Co., Ltd. on May 31, 2019 in Lianyungang. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- May 31, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Lianyungang (China)
Additional Details
Mutual Recognition Agreement (MRA)